ClinicalTrials.gg
CompletedNCT07798804Updated Sep 1, 2026

Frequency- and Intensity-Dependent After-Effects of High-Definition Transcranial Alternating Current Stimulation on Resting-State Electroencephalography

An interventional study of high-definition transcranial alternating current stimulation(HD-tACS) and sham high-definition transcranial alternating current stimulation(HD-tACS) in Schizophrenia With Auditory Hallucinations, sponsored by Shanghai Mental Health Center. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2025, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the after-effects of high-definition transcranial alternating current stimulation (HD-tACS) with varying parameters on resting-state brain activity in patients with schizophrenia experiencing auditory hallucinations.

02

Conditions studied

  • Schizophrenia With Auditory Hallucinations
03

In context

Hallucinations

136 studies on the registry are indexed under Hallucinations; 35 are open to participants now.

This study's enrollment of 36 is below the median of 48 across 118 interventional studies indexed under Hallucinations.

Browse Hallucinations studies →

Lead sponsor

Shanghai Mental Health Center is the lead sponsor of 272 studies on the registry; 91 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years;
  • Meet the diagnostic criteria for schizophrenia according to the , Fifth Edition (DSM-5);
  • Adequate verbal communication skills;
  • At least one auditory hallucination episode within the past week;
  • Willing to participate in the study and able to complete all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • History of neurological disorders, severe physical illness, traumatic brain injury, or craniotomy;
  • History of epileptic seizures or other neuropsychiatric disorders;
  • At risk for suicide, self-injury, or impulsive behavior.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    0.4mA-10Hz HD-tACS

    For 0.4mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    0.4mA-20Hz HD-tACS

    For 0.4mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 20 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    0.4mA-40Hz HD-tACS

    For 0.4mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 20 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    0.4mA-140Hz HD-tACS

    For 0.4mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    1mA-10Hz HD-tACS

    For 1mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    1mA-20Hz HD-tACS

    For 1mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    1mA-40Hz HD-tACS

    For 1mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    1mA-140Hz HD-tACS

    For 1mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    2mA-10Hz HD-tACS

    For 2mA-10Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    2mA-20Hz HD-tACS

    For 2mA-20Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    2mA-40Hz HD-tACS

    For 2mA-40Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    2mA-140Hz HD-tACS

    For 2mA-140Hz HD-tACS prevention, we will stimulate the personalized left or right temporal lobe channel at 10 Hz and 0.4mA.

    Device: high-definition transcranial alternating current stimulation(HD-tACS)

  • Experimental
    sham HD-tACS

    For sham HD-tACS, we will stimulate the personalized left or right temporal lobe channel using sham HD-tACS pattern.

    Device: sham high-definition transcranial alternating current stimulation(HD-tACS)

Interventions

  • Devicehigh-definition transcranial alternating current stimulation(HD-tACS)

    The active intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. Stimulation is administered for 90 seconds per condition, with the frequency and current intensity set according to the experimental protocol. A 10-second ramp-up and a 5-second ramp-down period are included in each stimulation condition. The stimulus waveform is sinusoidal. Stimulation is delivered using saline-soaked sponge electrodes. Electrode impedance is maintained below 10 kΩ throughout the stimulation session.

  • Devicesham high-definition transcranial alternating current stimulation(HD-tACS)

    The sham intervention consists of high-definition transcranial alternating current stimulation (HD-tACS) delivered using a 4×1 ring configuration (one center electrode surrounded by four return electrodes) over the personalized left or right temporal lobe. The return electrodes deliver one-quarter of the central electrode current with opposite polarity. To mimic the sensory experience of active stimulation, the sham condition includes a 10-second ramp-up and a 5-second ramp-down period at 0.4 mA and 140 Hz, with no current delivered during the intervening 90-second period.

06

What researchers measure

Primary outcomes

  1. Beta2-band EEG power at the stimulation site

    Changes in EEG power(dB) in beta2 band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

Secondary outcomes

  1. Alpha-band EEG power at the stimulation site

    Changes in EEG power(dB) in alpha band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  2. Delta-band EEG power at the stimulation site

    Changes in EEG power(dB) in delta band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  3. Theta-band EEG power at the stimulation site

    Changes in EEG power(dB) in theta band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  4. Gamma-band EEG power at the stimulation site

    Changes in EEG power(dB) in gamma band within different frequency band measured at the temporal lobe during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  5. Beta2-band functional connectivity measured by EEG wPLI

    Beta2-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  6. Alpha-band functional connectivity measured by EEG wPLI

    Alpha-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  7. Delta-band functional connectivity measured by EEG wPLI

    Delta-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  8. Theta-band functional connectivity measured by EEG wPLI

    Theta-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

  9. Gamma-band functional connectivity measured by EEG wPLI

    Gamma-band functional connectivity between predefined EEG electrodes, quantified using the weighted Phase Lag Index (wPLI), during the 180-second resting-state EEG recording immediately following each stimulation condition.

    Time frame: 180-second recording after each 90-second stimulation

07

Study locations

1 site
  • Fuyang Mental Heath Center
    Fuyang, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available because of privacy and confidentiality considerations related to the collection of electrophysiological data from human participants.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07798804
Responsible party
Haifeng Jiang (associate chief physician, Shanghai Mental Health Center) — Principal investigator
First posted
Sep 1, 2026
Start date
Dec 5, 2025
Primary completion
Feb 11, 2026
Completion
Feb 15, 2026
Last update
Sep 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion